The Study
APOE4 to APOE2 allelic switching in mice improves Alzheimer’s disease-related metabolic signatures, neuropathology and cognition
This study is like doing a science experiment with genetically changed mice — they switched one gene for another and saw that the mice’s brains changed in some ways. But it doesn’t prove that doing this in people would help with Alzheimer’s — it’s just a first step in a lab.
Analysis score
Maximum 58 for a case-control study.
Where the score came from
Scientists made mice that can switch their Alzheimer’s-risk gene (APOE4) to a protective version (APOE2) like flipping a switch. They did this only in brain support cells called astrocytes.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 516 / 100
Quality score
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes—reducing plaques and improving memory in mice suggests this gene switch could be a powerful future therapy, but it also raised a safety concern: switching the gene everywhere caused unhealthy high blood fats.
- 2After switching, mice had 30–40% fewer brain plaques, less inflammation around plaques, and better memory on some tests.
- 3Their brain fats and genes also changed in ways linked to Alzheimer’s protection.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Nature Neuroscience
Year
2025
Authors
L. Golden, Dahlia Siano, Isaiah O. Stephens, Steven M. MacLean, Kai Saito, Georgia L Nolt, Jessica L. Funnell, Akhil Pallerla, Sangderk Lee, Cathryn T. Smith, Jing Chen, Haining Zhu, Clairity Voy, Callie M Whitus, Gabriela Hernandez, Brandon C Farmer, Kumar Pandya, Dale O. Cowley, S. Macauley, Scott M. Gordon, J. Morganti, Lance A. Johnson
Related Content
Claims (4)
In adult mice, changing a specific protein produced by astrocytes from APOE4 to APOE2 reduces activation of nearby microglial cells and lowers the activity of genes linked to neurodegenerative disease.
In genetically modified mice, changing the APOE4 gene to APOE2 specifically in astrocytes reduces amyloid plaques in brain regions linked to memory and decreases inflammation around plaques, while improving performance in memory tasks.
In mice, changing the APOE gene in astrocytes from APOE4 to APOE2 changes gene activity in nearby brain cells, including microglia and oligodendrocytes, even though those cells still produce APOE4.
In adult mice, replacing the APOE4 gene variant with the APOE2 gene variant results in higher levels of ApoE protein in the brain and changes in lipid composition, specifically increasing phosphatidylcholine molecules that are associated with Alzheimer’s disease pathology and glial cell metabolic activity.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.